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Objectives: To compare 2-year outcomes of total knee replacement (TKR) followed by non-27 
surgical treatment to that of non-surgical treatment alone and outcomes of the same non-surgical 28 
treatment to that of written advice. 29 
Design: In two randomized trials, 200 (mean age 66) adults with moderate to severe knee 30 
osteoarthritis (OA), 100 eligible for TKR and 100 not eligible for TKR, were randomized to TKR 31 
followed by non-surgical treatment, non-surgical trea ment alone, or written advice. Non-surgical 32 
treatment consisted of 12 weeks of supervised exercise, education, dietary advice, use of insoles, 33 
and pain medication. The primary outcome was the mean score of the Knee Injury and 34 
Osteoarthritis Outcome Score subscales, covering pain, symptoms, activities of daily living, and 35 
quality of life. 36 
Results: Patients randomized to TKR had greater improvements than patients randomized to non-37 
surgical treatment alone (difference of 18.3 points (95% CI; 11.3 to 25.3)), who in turn improved 38 
more than patients randomized to written advice (difference of 7.0 points (95% CI; 0.4 to 13.5)). 39 
Among patients eligible for TKR, 16 (32%) from the non-surgical group underwent TKR during 2 40 
years and among those initially ineligible, seven patients (14%) from the non-surgical group and ten 41 
(20%) from the written advice group underwent TKR.  42 
Conclusions: TKR followed by non-surgical treatment is more effective on pain and function than 43 
non-surgical treatment alone, which in turn is more eff ctive than written advice. Two out of three 44 
patients with moderate to severe knee OA eligible for TKR delayed surgery for at least 2 years 45 
following non-surgical treatment. 46 
Trial registration: ClinicalTrials.gov numbers NCT01410409 and NCT01535001. 47 
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 49 
INTRODUCTION 50 
Knee osteoarthritis (OA) is a leading contributor to the global burden of disease 1. About 14 million 51 
people in the US have symptomatic knee OA, more than half are younger than 65 years of age 2, 52 
and OA is the second most common non-acute reason for seeking healthcare 3. The prevalence of 53 
knee OA has increased substantially during the last 20 years 4 and is expected to continue to 54 
increase 1. As the total cost associated with treating OA has been estimated to be 1-2.5% of the 55 
gross domestic product in the US and other westerniz d countries 5, an increased prevalence will 56 
have extensive societal impact. Healthcare settings across the globe need to prepare for this increase 57 
by strengthening the evidence base for different OA treatment strategies.  58 
Patient education, exercise therapy, and weight control are recommended core treatments for all 59 
patients with knee OA in most international guidelin s 6. If needed, additional biomechanical and 60 
pharmacological interventions can be prescribed, based on the characteristics and preferences of the 61 
individual patient 7,8. In patients with end-stage knee OA, total knee replacement (TKR) is an 62 
effective treatment 9 although approximately 20% still have long-term pain after the surgery 10. 63 
Until recently, no high quality trials had investigated the effectiveness of TKR despite a rapid 64 
increase in TKR procedures each year 11. 65 
We previously reported the one-year results from a trial comparing the addition of TKR to non-66 
surgical treatment alone and a trial comparing the same non-surgical treatment to written advice 67 
12,13. The two trials were similarly designed, used the same individualized supervised non-surgical 68 
treatments and outcomes, and were conducted in parallel with patients recruited by the same 69 
surgeons and sites 14,15. Across trials, patients were of similar age and repo ted similar baseline pain 70 
Downloaded for Anonymous User (n/a) at Aalborg University Hospital from ClinicalKey.com by Elsevier on May 09, 2018.
















levels 16. The major differences were the patients’ eligibility for TKR 14,15 and their radiographic 71 
OA severity 16.  72 
The purpose of this study was to report the 2-year outcomes from the two parallel trials. Combined 73 
reporting of the two trials allowed more in-depth comparison of available treatment options, thereby 74 
supporting evidence-informed shared decision-making. The three different treatment strategies 75 
tested in patients with symptomatic knee OA ranged from a minimal intervention, written advice, to 76 
a moderate, supervised non-surgical treatment, throug  to a maximal intervention of TKR followed 77 
by supervised non-surgical treatment.  78 
 79 
METHODS 80 
Trial design 81 
This paper reports the baseline to 2-year results from two two-arm parallel group assessor-blinded 82 
RCTs (1:1 ratio) and conforms to the CONSORT statement for reporting RCTs 17.  83 
Ethics approvals for this extended follow-up were obtained in the original protocol submitted to the 84 
local Ethics Committee of The North Denmark Region (N-20110024 and N-20110085) and the 85 
studies were registered at ClinicalTrials.gov (NCT01410409 and NCT01535001). 86 
Full details about the process for recruitment, crieria for eligibility, the randomization procedure, 87 
allocation concealment and detailed description of the interventions have been previously published 88 
14,15.  89 
Randomization procedure and allocation concealment 90 
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A priori, the randomization schedule was generated separately for the two trials in permuted blocks 91 
of eight, stratified by site, and the allocation numbers were concealed in sealed, opaque envelopes 92 
prepared by a staff member independent of the study. One research assistant at each site had access 93 
to the envelopes, opening them only when informed consent and baseline outcomes had been 94 
obtained. 95 
Participants 96 
Patients were recruited between September 2011 and December 2013 from the Department of 97 
Orthopedics in the Northern Denmark Region, Denmark. Two hundred patients with symptomatic 98 
knee OA considered eligible (n=100) 14 or not eligible (n=100) 15 for TKR were included in the 99 
studies. All patients provided informed written conse t before participation. 100 
The two RCTs 14,15 had two major, shared exclusion criteria: 1) mean p i  the previous week above 101 
60 mm on a 100 mm visual analogue scale, and 2) previous knee replacement on the same side. 102 
The RCT randomizing to TKR in addition to non-surgical treatment 12 had two major inclusion 103 
criteria: 1) considered eligible for TKR by the orthopedic surgeon - a decision among others factors 104 
typically based on pain, function and radiographic severity 9, and 2) diagnosed with radiographic 105 
knee OA (Kellgren-Lawrence (K&L) score ≥2 on the original scale) 18 and one additional major 106 
exclusion criterion: 1) need for bilateral simultaneous TKR.  107 
The RCT randomizing to non-surgical treatment or written advice 13 had two major inclusion 108 
criteria: 1) considered not eligible for TKR by the orthopedic surgeon, 2) diagnosed with 109 
radiographic knee OA (K&L score ≥1 on the original scale) 18 and one additional major exclusion 110 
criterion: 1) a score more than 75 on the 0 (worst) to 100 (best) self-reported Knee Injury and 111 
Osteoarthritis Outcome Score (KOOS)4, defined as the average score for the subscale scor s for 112 
pain, symptoms, activities of daily living (ADL) and quality of life (QOL) 19. 113 
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The major differences between patients in the two RCTs were their radiographic OA severity, level 114 
of functional limitation and whether they were eligible for TKR or not, while they were of similar 115 
age and had similar baseline pain intensity 16. 116 
Interventions 117 
One RCT randomized patients eligible for TKR to eith r TKR followed by supervised non-surgical 118 
treatment or to supervised non-surgical treatment alo e 14, while the other RCT randomized patients 119 
not eligible for surgery to either supervised non-surgical treatment or to written advice (Figure 1) 15. 120 
The content and administration mode of the supervisd non-surgical treatment program was 121 
identical in the three groups receiving that treatment, while the fourth group received written advice 122 
only. 123 
****** Figure 1 HERE******** 124 
 125 
Total knee replacement 126 
Surgical patients had a total cemented prosthesis with patellar resurfacing (NexGen, CR-Flex, fixed 127 
bearing or LPS-Flex, fixed bearing, Zimmer, Warsaw, Indiana, USA), performed by high-volume 128 
orthopedic specialists using surgical methods recommended by the manufacturer 20. 129 
 130 
Supervised non-surgical treatment 131 
The 3-month individualized, non-surgical treatment program included exercise, patient education, 132 
and insoles, while weight loss and/or pain medication were prescribed if indicated. The treatments 133 
were delivered by physiotherapists and dieticians at Aalborg University Hospital, Denmark. 134 
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The NEuroMuscular EXercise training program (NEMEX), previously demonstrated to be feasible 136 
in patients with moderate to severe knee OA 21, was administered in 1-hour physiotherapist-137 
supervised group-based sessions twice weekly. The program focuses on building compensatory 138 
functional stability and improving sensorimotor contr l and has different levels of difficulty for 139 
each individual exercise 21. After 12 weeks of exercise, the patients underwent a transition period of 140 
8 weeks, where the exercise program was increasingly performed at home to improve long-term 141 
adherence. 142 
Patient education 143 
Two 60-minute group-based educational sessions were given, actively engaging the patients in their 144 
treatment, which focused on disease characteristics, advice on treatment and self-help.  145 
 146 
Dietary advice 147 
Patients with a body mass index ≥25 at baseline consulted a dietician with the overall aim of 148 
reducing body weight by at least 5% 22. The weight loss program was based on principles from 149 
motivational interviewing 23 and consisted of four individual 1-hour sessions.  150 
Insoles 151 
The patients received individually fitted full-length Formthotics Original Dual Medium (perforated) 152 
insoles with medial arch support (Foot Science International, Christchurch, New Zealand). A 4° 153 
lateral wedge was added to the insoles of patients with a knee-lateral-to-foot position (the knee 154 
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moves over or lateral to the 5th toe in three or moe of five trials) as tested with the valid and 155 
reliable Single Limb Mini Squat Test 24.  156 
Pain medication 157 
Paracetamol 1 g four times daily, ibuprofen 400 mg three times daily, and pantoprazole 20 mg daily 158 
were prescribed if indicated. The prescription was reassessed every 3 weeks and the patients were 159 
instructed to contact the physiotherapist if they were uncertain about the need for continued pain 160 
medication.  161 
Booster sessions 162 
After the 12-week intervention period and the 8-week transition period and until the 12-month 163 
follow-up, a physiotherapist contacted the patients monthly by telephone to support exercise 164 
adherence. Patients participating in the dietary intervention were telephoned twice (30-minute calls 165 
26 and 39 weeks after initiating the non-surgical treatment) by the dietician to support dietary 166 
adherence. 167 
Written advice 168 
Patients were given two standardized information leaflets: One with information on knee OA 169 
etiology, symptoms, common functional limitations, recommended treatments and general advice 170 
on how to address the symptoms, and the other, containi g information on where to seek advice on 171 
treatment and how to achieve a healthy lifestyle. This was considered usual care for patients with 172 
knee OA at the time the study was conducted. 173 
 174 
Outcomes 175 
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Baseline, 3, 6, 12 and 24 months follow-up visits took place at the Department of Occupational 176 
Therapy and Physiotherapy, Aalborg University Hospital, Denmark. The assessor was specifically 177 
trained in all aspects of the assessments, was blinded to treatment allocation and was not affiliated 178 
with either treatment site. In the trial of TKR 12, to maintain blinding, all patients were asked to 179 
cover the study knee with three layers of white elastic tape before meeting with the assessor, 180 
thereby covering a potential surgical scar. 181 
Primary outcome 182 
The primary outcome was the between-group difference i  change from baseline to 2-year follow-183 
up in KOOS4, with scores ranging from 0 (worst) to 100 (best). KOOS4 is the mean score of four 184 
out of five KOOS subscales covering Pain, Symptoms, ADL and QOL, each consisting of multiple 185 
items scored from 0-4 on a Likert scale 25,26. KOOS is a valid, reliable and responsive patient-186 
reported outcome measure for both short-term and log-term follow-up of patients with knee OA 187 
and TKR 19.  188 
Secondary outcomes 189 
Secondary outcomes included change from baseline to the 2-year follow-up in 1) the five KOOS 190 
subscale scores (the fifth being Function in sport and recreation) to assist clinical interpretation of 191 
the primary outcome (0-100; worst to best) 27;  2) time from the Timed Up-and-Go Test 28 and mean 192 
time for two 20-meter walk tests (shorter time is better) 29; 3) weight (kg) measured without shoes 193 
and outdoor clothing at the same time of day using the same scale (seca 813, Seca Gmbh & Co. 194 
Kg., Hamburg, Germany); and 4) type, dosage, and quantity of pain medication taken the previous 195 
week. Intake was dichotomized into yes/no due to non-uniformity of the distribution of pain 196 
medication intake. 197 
Total knee replacements and revision surgery during follow-up 198 
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The number of patients undergoing TKR and revision urgery during follow-up was identified 199 
through the hospital records and the Danish National Patient Registry, where all patient contacts 200 
with public and private hospitals and clinics in Denmark are registered. 201 
 202 
Statistical analysis 203 
Sample size 204 
For both studies, the sample size was based on the primary outcome KOOS4 
25,26. The sample size 205 
needed to detect a 10-point difference (SD 14) betwe n groups in KOOS4 was 41 patients in each 206 
group (power of 90% and p=0.05). To account for missing data a total of 100 patients were 207 
randomized in both studies.  208 
Two-year analyses 209 
The analyses of the 2-year results followed the same procedure as the analyses of the two primary 210 
reports 12,13. This procedure was pre-defined in the two statistical analysis plans, which were made 211 
publically available before any analyses of the primary reports commenced 30,31. An independent 212 
statistician performed all analyses. 213 
All primary and secondary outcomes underwent intention-to-treat analyses. The intention-to-treat 214 
population included those randomized to the two treatm nt arms of the respective trials (n=100 in 215 
each trial). As the focus of this report was to investigate the effects of different treatment strategies 216 
ranging from a minimal to a maximal intervention for patients with knee OA, no per-protocol 217 
analyses are reported.  218 
The analyses were performed separately for the two RCTs. Between-group comparisons of 219 
treatment effect for all primary and secondary outcmes, except for pain medication, were 220 
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performed using a linear mixed effects model with patient as a random factor and follow-up time 221 
(baseline, 3, 6, 12 and 24 months), treatment arm (TKR followed by non-surgical treatment, non-222 
surgical treatment)/(non-surgical treatment, written advice), site (Frederikshavn, Farsoe). 223 
Interaction between follow-up and treatment arm were also included in the model. Crude and 224 
adjusted (follow-up, site and interaction between follow-up and treatment arm) analyses were 225 
performed. To assess superiority, mean between-group differences in changes from baseline and 226 
two-sided 95% CI are presented. In the analyses of weight change following treatment, only 227 
patients with a body mass index ≥25 at baseline were included, as they were the only ones offered 228 
consultations with a dietician. A figure including data from all timepoints (baseline, 3, 6, 12 and 24 229 
months) is presented to visualize change over time in KOOS4 and the 20-meter walk test. 230 
The relative risk of using pain medication was compared between groups using a modified Poisson 231 
regression model with a robust error variance for the confidence intervals and accounting for 232 
clustering at patient level 32.  233 
Number needed to treat analyses were performed in both trials, estimating the number of people 234 
who needed to undergo the evaluated treatment for one person to have a 15% improvement 33,34 in 235 
KOOS4 and the KOOS subscale scores, from baseline to the 2-year follow-up 
35,36. 236 
A CI excluding 0 (1 for proportions) was considered sufficient to reject the null hypothesis and 237 
conclude that there was a difference in treatment effect. . All analyses were carried out in Stata 14 238 
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Patient characteristics 244 
Baseline characteristics of the four groups of patients and patient flow are presented in Figure 2 and 245 
Table 1, respectively.  246 
*****Figure 2 HERE**** 247 
 248 
****** Table 1 HERE **** 249 
In the trial of patients eligible for TKR where 100 patients were randomized, 2-year follow-up data 250 
were available for 47/50 (94%) in the non-surgical treatment group and 43/50 (86%) in the TKR 251 
followed by non-surgical treatment group. Administrative data revealed that 16 out of 50 patients 252 
(32%) from the non-surgical treatment group had a TKR before the 2-year follow-up (mean 253 
duration from initiating the non-surgical treatment (range) 8.7 (2.6 to 21.5) months); three patients 254 
between 1 and 2 years). One of 50 patients in the TKR followed by non-surgical treatment group 255 
decided not to undergo TKR. One patient in the TKR followed by non-surgical treatment group had 256 
three revision surgeries ending up with the prosthesis being removed and the knee fused because of 257 
deep infection. Three patients in the TKR followed by non-surgical treatment group and one patient 258 
in the non-surgical treatment group, who had severe kne  stiffness during the rehabilitation period 259 
after TKR, required manipulation of the knee while th y were under anesthesia. The mean follow-260 
up time after initiation of the non-surgical treatment was 24.0 and 24.3 months in the TKR followed 261 
by non-surgical treatment group and the non-surgical tre tment group, respectively.  262 
In the trial of patients not eligible for TKR where 100 patients were randomized, 2-year follow-up 263 
data were available for 46/50 (92%) in the supervisd non-surgical treatment group and 42/50 264 
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(84%) in the written advice group. Seven patients (14%) from the supervised non-surgical treatment 265 
group and ten (20%) from the written advice group had a TKR during the 2 years (mean duration 266 
from being included in the trial (range) 12.5 (0.7 to 20.7) and 12.1 (range 3.4 to 19.4) months, 267 
respectively). In the written advice group, one patient required manipulation of the knee under 268 
anesthesia after TKR and one patient had arthroscopic partial synovectomy due to non-infectious 269 
synovitis after TKR. The mean follow-up time after baseline was 24.9 and 24.5 months in the 270 
supervised non-surgical treatment group and written advice group, respectively.  271 
 272 
Outcomes 273 
Patients eligible for TKR 274 
The TKR followed by non-surgical treatment group had a greater adjusted improvement (95% CI) 275 
of 18.3 (11.3 to 25.3) in KOOS4 compared to the non-surgical treatment group (Figure 3 and Table 276 
2). The TKR followed by non-surgical treatment group improved by 34.6 (28.4 to 40.8) in KOOS4 277 
from baseline to the 2-year follow-up, while the non-surgical treatment group improved by 16.1 278 
(9.2 to 23.0).  279 
 280 
***** Figure 3 HERE***** 281 
***** Table 2 HERE****** 282 
 283 
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Furthermore, the TKR followed by non-surgical treatment group had greater improvements in all 284 
secondary outcomes, except for weight, where the non-surgical treatment group had greater 285 
improvements (Figure 4, Table 2-3).   286 
*****Figure 4 HERE***** 287 
***** Table 3 HERE ***** 288 
 289 
4-5 patients would need to undergo TKR in addition o on-surgical treatment for one patient to 290 
have a clinically-relevant improvement, i.e. a 15% improvement in KOOS4 (Table 4). 291 
 292 
***** Table 4 HERE ***** 293 
 294 
Patients not eligible for TKR 295 
The supervised non-surgical treatment group had a gre ter adjusted improvement (95% CI) of 7.0 296 
(0.4 to 13.5) in KOOS4 compared to the written advice group (Fig 3, Table 2).  The supervised non-297 
surgical treatment group improved by 18.5 (13.0 to 24.0) in KOOS4 from baseline to the 2-year 298 
follow-up, while the written advice group improved by 11.6 (5.9 to 17.2).  299 
Furthermore, the supervised non-surgical treatment group had greater improvements in KOOS 300 
subscale ADL (Fig 4, Table 2-3).  8 patients would need to undergo the non-surgical treatment for 301 
one patient to have a clinically-relevant improvement, i.e. a 15% improvement in KOOS4 (Table 4). 302 
 303 
 304 
Downloaded for Anonymous User (n/a) at Aalborg University Hospital from ClinicalKey.com by Elsevier on May 09, 2018.

















This report of two parallel RCTs showed that TKR followed by supervised non-surgical treatment 306 
(maximal intervention) resulted in twice the improvement in pain and function compared to a 307 
strategy of supervised non-surgical treatment with the option of TKR later (moderate intervention), 308 
which, in turn, resulted in a 60% greater improvement than a strategy of written advice (minimal 309 
intervention) after 2 years. Two out of three patients with moderate to severe knee OA eligible for 310 
TKR delayed surgery for at least 2 years following supervised non-surgical treatment. 311 
Our finding of similar baseline pain levels between the two RCTs 16 confirms previous findings of a 312 
large overlap in preoperative symptoms among patients found eligible or not eligible for TKR 37,38. 313 
On the other hand, we found that patients eligible for TKR had worse function and more severe 314 
radiographic OA 16. These findings underline the complexity associated with deciding on a 315 
treatment strategy matching the individual patient and their preferences 16,39 and the resulting lack 316 
of consensus about the indications for TKR 9,40,41.  317 
The minimal important change is difficult to define and varies with methodological approach, 318 
patient characteristics and interventions undertaken 42,43 with more invasive and costly procedures, 319 
such as surgery, potentially requiring a larger improvement to represent a clinically meaningful 320 
improvement. In this study, we chose an operational cut-off of 15% to compare the proportions with 321 
clinically important improvements 33,34. We found that at 2 years, more than half the patients had 322 
improved 15%, regardless of the intervention. This finding suggests that a variety of treatments 323 
might be beneficial for patients with knee OA with symptoms severe enough to consult with an 324 
orthopedic surgeon. As expected, the proportion of patients who improved was the lowest for 325 
written advice (57%), increased for supervised non-surgical management (70% and 64%, 326 
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respectively) and was the highest for patients receiving TKR in addition to supervised non-surgical 327 
management where 86% reported an improvement of at least 15% at 2 years.  328 
All treatment groups, including the written advice group, improved gradually from baseline to the 329 
1-year follow-up. Although pain and functional limitations were still present in all groups, 330 
especially in patients who had not undergone TKR, our results confirmed the expected outcomes 331 
after TKR, and we found the short-term non-surgical treatments and written advice were still 332 
effective after 2 years. The average improvements from non-surgical treatment and written advice 333 
were sustained from 1 to 2 years, with only one out of three found eligible for surgery at baseline 334 
opting for TKR during the 2-year follow-up period, compared to 17% of patients found not eligible. 335 
Our results are consistent with previous studies demonstrating larger long-term improvements from 336 
a combined non-surgical treatment of exercise and education compared to usual care 33, and 337 
exercise and weight loss compared to either intervention alone 44 or usual care 45. 338 
Comorbidities are common in patients with OA46,47 and therefore treatments potentially able to 339 
modify risk factors for diabetes, cardiovascular disease and other comorbidities, such as body 340 
weight and intake of pain medication, may be preferable. Our results were conflicting concerning 341 
modification of risk factors. Those randomized to TKR had a weight gain of 2.7 kg but only half the 342 
risk of taking pain medication during the previous week compared to those randomized to 343 
supervised non-surgical management alone. While the non-surgical treatment group consequently 344 
had approximately twice the risk of taking pain medication the previous week, their weight loss was 345 
maintained with a 2.2 kg reduction at 2 years. 346 
Shared-decision making processes should include both benefits and harms from the potential 347 
treatment options. We found that patients undergoing TKR had a higher risk of experiencing knee-348 
related serious adverse events compared to patients having non-surgical management only (8 vs. 0 349 
Downloaded for Anonymous User (n/a) at Aalborg University Hospital from ClinicalKey.com by Elsevier on May 09, 2018.
















events in the as-treated analysis), including four manipulation under anesthesia due to knee 350 
stiffness, three deep venous thromboses requiring antico gulant treatment and one deep infection 12. 351 
Importantly, the rate of serious adverse events in our study should be evaluated with caution due to 352 
the small sample size. However, the finding supports current treatment guidelines for knee OA, 353 
including patients with symptoms severe enough to consult with an orthopedic surgeon, suggesting 354 
a stepwise approach starting with patient education, exercise and weight loss if needed, progressing 355 
to additional treatment such as analgesics and finally surgery if sufficient pain relief and functional 356 
improvement is not achieved 7,48 to balance treatment effects and the potential for harms. 357 
 358 
Strengths and limitations 359 
As both trials had mean pain the previous week above 60 mm on a 100 mm visual analogue scale as 360 
an exclusion criteria, our results cannot be generaliz d to all patients seen by the orthopedic 361 
surgeon. However, 42% of patients eligible for TKR in our trial reported pain higher than 60 mm 362 
when asked about worst pain during the previous 24 hours at baseline. Furthermore, the mean 363 
KOOS Pain subscale score in our trial of patients eligible for TKR of 49 is comparable to a number 364 
of previous clinical studies evaluating pain severity prior to TKR 38,49,50. Twelve percent of patients 365 
eligible for TKR had mild radiographic OA severity (K&L of 2), which is similar to previous 366 
clinical cohorts of patients eligible for TKR demonstrating that 9-12% of patients found eligible for 367 
TKR have mild OA 38,51,52. Altogether, this suggests that our results can be generalized to the 368 
majority of the knee OA population referred to a surgeon. 369 
The majority of the pain relief in OA treatment studies is attributable to placebo or contextual 370 
factors and not the specific effects from the treatments given 53,54. Furthermore, invasive 371 
procedures, such as TKR, have a stronger placebo effect than less invasive, such as pain medication 372 
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and exercise 55. As such, our trials would have benefitted from including groups receiving placebo 373 
treatments, including sham surgery. A strength of our study is however that we included objective 374 
tests of physical function, which are less prone to placebo effects than patient-reported outcomes, 375 
that largely confirmed the primary between-group findings. The analysis of weight change at 2 376 
years only included patients with a body-mass index of 25 or higher at baseline, as they were the 377 
only ones offered consultations with a dietician. As the randomization was not stratified on body-378 
mass index, this might affect the results on weight change. Finally, since the non-surgical treatment 379 
strategy included a multimodal treatment approach, identifying the effect from the individual 380 
treatments is not possible. On the other hand, the multi-modal approach resembles current treatment 381 
guidelines 7,8 thereby increasing the applicability of our result to clinical practice, but more 382 
controlled trials are recommended to investigate which of the individual interventions combined in 383 
the non-surgical regimes provide the most benefit and which do not. 384 
 385 
CONCLUSIONS 386 
TKR followed by supervised non-surgical treatment (maximal intervention) resulted in twice the 387 
improvement in pain and function after 2 years compared with non-surgical treatment with the 388 
option of TKR later (moderate intervention) in patients with knee OA eligible for TKR. Applying 389 
the same supervised non-surgical treatment (moderate intervention) in patients with knee OA not 390 
eligible for TKR resulted in a 60% greater improvement than written advice (minimal intervention). 391 
Two out of three patients with moderate to severe knee OA eligible for TKR delayed surgery for at 392 
least 2 years following non-surgical treatment. Physicians, surgeons and patients are encouraged to 393 
discuss benefits and harms of both surgical and non-surgical treatment options to optimize timing of 394 
available treatment options to meet the preferences and expectations of the individual patient. 395 
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FIGURE LEGENDS 639 
 640 
Figure 1. Interventions in the two randomized controlled trials 641 
Figure 2. Flow of patients in the randomized controlled trial of patients eligible (a) and not 642 
eligible (b) for total knee replacement. TKR=Total knee replacement; K-L score= Kellgren-643 
Lawrence score; KOOS4=The average score for the subscale scores for pain, symptoms, activities 644 
of daily living and quality of life from the Knee injury and Osteoarthritis Outcome Score, 645 
VAS=Visual Analogue Scale. 646 
Figure 3. Mean score from the primary outcome of the Knee injury and Osteoarthritis Outcome 647 
Score (KOOS4; 0-100; worst to best scale) covering Pain, other Symptoms, Function in daily living 648 
(ADL), and knee-related Quality of life (QOL)) at baseline and at 3, 6, 12 and 24 months follow-649 
ups for all four groups from the two randomized contr lled trials. TKR: Total knee replacement. * 650 
Indicates differences in change from baseline to 24 months between the TKR followed by non-651 
surgical group and the non-surgical only group, and between the non-surgical group and the written 652 
advice group, respectively. Data from 3, 6 and 12 months are from the primary reports.12,13 653 
Figure 4. Mean time (sec) in the 20-meter walk test at baseline and at 3, 6, 12 and 24 months 654 
follow-ups for all four groups from the two randomized controlled trials. TKR: Total knee 655 
replacement. * Indicates differences in change from baseline to 24 months between the TKR 656 
followed by non-surgical group and the non-surgical only group. The difference in change from 657 
baseline to 24 months between the non-surgical group and the written advice group did not reach 658 
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Patients eligible for TKR Patients not eligible forTKR 
TKR followed by non-
surgical group 
Non-surgical group Non-surgical group Written advice group 
Women, n (%) 32 (64) 30 (60) 26 (52) 25 (50) 
Age (years), mean (SD) 65.8 (8.7) 67.0 (8.7) 64.8 (8 7) 67.1 (9.1) 
Body Mass Index, mean (SD) 32.3 (6.2) 32.0 (5.8) 30.6 (5.6) 29.4 (5.2) 
Bilateral knee pain, n (%) 18 (36) 17 (34) 18 (36)  21 (42) 
Radiographic knee OA severity  
(Kellgren-Lawrence), n (%) 
    Grade 1 0 (0) 0 (0) 7 (14) 11 (22) 
    Grade 2 7 (14) 5 (10) 13 (26) 15 (30) 
    Grade 3 21 (42) 21 (42) 13 (26) 10 (20) 
    Grade 4 22 (44) 24 (48) 17 (34) 14 (28) 
KOOS scores 
    KOOS4 47.4 (13.4) 48.5 (11.4) 48.9 (11.8) 53.2 (12.1) 
    Pain 48.6 (17.5) 49.5 (13.1) 51.6 (14.3) 53.6 (13.7) 
    Symptoms 54.0 (15.0) 58.3 (15.2) 54.6 (15.9) 59.5 (18.3) 
    ADL 55.0 (17.0) 53.5 (14.2) 55.5 (17.1) 60.4 (16.4) 
    Sport/Rec 18.0 (14.7) 16.7 (15.1) 24.5 (18.2) 23.0 (16.5) 
    QOL 32.3 (15.3) 32.7 (13.3) 34.0 (12.4) 39.5 (14.5) 
   Time (s) from the Timed Up and Go test 9.4 (2.4) 8.6 (2.1) 7.8 (2.3) 8.1 (2.5) 
   Time (s) from the 20-meter walk test 13.4 (3.7) 12.2 (2.6) 10.9 (2.3) 11.0 (2.4) 
Used pain medication in the last week, n (%) 33 (67) 29 (58) 32 (64) 30 (60) 
a Radiographic severity: Radiographic knee osteoarthritis severity on the Kellgren-Lawrence scale; KOOS4: The mean score of four out of five of the 
Knee injury and Osteoarthritis Outcome Score subscale  covering Pain, Symptoms, Function in daily living (ADL) and Quality of life (QOL), with 
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Table 2. Outcomes at 2 years for patients eligible (n=100) and not eligible (n=100) for total knee replacement (TKR) a673 
Outcome 
Patients eligible for TKR Patients not eligible for TKR 
Mean Improvement (95% CI) 
Between-Group Difference in 
Mean Improvement (95% CI) 
Mean Improvement (95% CI) 
Between-Group Difference in 













    KOOS4 34.6 (28.4 to 
40.8) 




18.3 (11.3 to 
25.3) 
18.5 (13.0 to 
24.0) 
11.6 (5.9 to 
17.2) 
7.0 (0.4 to 
13.5) 




    Pain 36.2 (28.8 to 
43.7) 
18.9 (11.2 to 
26.6) 
17.3 (9.1 to 
25.5) 
17.3 (9.1 to 
25.5) 
20.0 (14.0 to 
26.0) 
14.2 (7.8 to 
20.5) 
5.8 (-1.8 to 
13.5) 
5.8 (-1.8 to 
13.5) 
    Symptoms 29.0 (23.3 to 
34.7) 
12.8 (5.6 to 
20.0) 
16.3 (9.0 to 
23.6) 
16.3 (9.0 to 
23.6) 
15.8 (9.1 to 
22.4) 
11.7 (5.6 to 
17.7) 
4.1 (-3.1 to 
11.3) 
4.1 (-3.1 to 
11.4) 
    ADL 30.4 (23.6 to 
37.2) 
14.9 (7.7 to 
22.1) 
15.1 (7.6 to 
22.6) 
15.1 (7.5 to 
22.6) 
19.6 (13.5 to 
25.7) 
9.5 (2.1 to 
16.8) 
10.1 (2.8 to 
17.5) 
10.1 (2.7 to 
17.5) 
    Sport/Rec 39.2 (31.9 to 
46.5) 
20.3 (10.4 to 
30.2) 
18.1 (8.7 to 
27.5) 
18.1 (8.7 to 
27.6) 
13.8 (5.4 to 
22.2) 
18.9 (11.4 to 
26.4) 
5.1 (-4.0 to 
14.3) 
5.1 (-4.1 to 
14.2) 
    QOL 42.3 (34.0 to 
50.6) 




24.1 (15.6 to 
32.6) 
18.8 (12.4 to 
25.1) 
11.0 (4.2 to 
17.8) 
7.7 (-0.1 to 
15.6) 
7.7 (-0.2 to 
15.6) 
Timed Up-and-
Go test (s) 
-3.1 (-3.8 to -
2.3) 
-1.5 (-2.1 to 
-0.9) 
1.5 (0.7 to 
2.3) 
1.5 (0.7 to 2.3) -1.3 (-1.8 to -
0.7) 
-1.2 (-1.6 to -
0.7) 
0.1 (-0.7 to 
0.9) 




-3.2 (-4.1 to -
2.3) 
-1.0 (-1.7 to 
-0.2) 
2.2 (1.2 to 
3.2) 
2.2 (1.2 to 3.2) -1.1 (-1.6 to -
0.7) 
-0.6 (-1.4 to 
0.1) 
0.5 (-0.4 to 
1.4) 
0.5 (-0.4 to 
1.4) 
Weight (kg) 2.7 (-2.9 to 
8.2) 
-2.2 (-3.5 to 
-0.8) 
4.8 (2.2 to 
7.5) 
.8 (2.2 to 7.5) -1.1 (-2.7 to 0.5) -1.6 (-3.2 to -
0.1) 
0.5 (-1.0 to 
1.9) 
0.5 (-1.0 to 
2.0) 
a Total knee replacement (TKR): KOOS4: The mean score of four out of five of the Knee injury and Osteoarthritis Outcome Score subscales covering 
Pain, Symptoms, Function in daily living (ADL) and Quality of life (QOL), with scores ranging from 0 to 100 (worst to best scale); Sport/Rec: Function 
in sport and recreation. The results were adjusted for time of follow-up (baseline, 3, 6, 12 and 24 months), site (Frederikshavn or Farsoe) and the 
interaction between time of follow-up and treatment arm; Data for weight is presented only for patients with a body-mass index of 25 or higher at 
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Table 3. Usage of pain medication at 2 years a 675 
Outcome Patients eligible for TKR Patients not eligible forTKR 
TKR followed by 
non-surgical group 
Non-surgical group Non-surgical group Usual care group 
Proportion of users of pain medication1  
Baseline  0.67 (0.53 to 0.79) 0.60 (0.46 to 0.73) 0.64 (0.50 to 0.76) 0.60 (0.46 to 0.73) 
24 months 0.26 (0.15 to 0.41) 0.49 (0.35 to 0.63) 0.41 (0.28 to 0.56) 0.52 (0.37 to 0.67) 
Risk ratio for taking pain medication at 24 months vs. baseline 
Adjusted estimate 0.38 (0.22 to 0.64) 0.82 (0.57 to 1.17) 0.65 (0.45 to 0.93) 0.88 (0.65 to 1.19) 
Risk ratio for taking pain medication at 24 months in non-surgical group vs. TKR followed by non-surgical 
group and written advice group vs. non-surgical group 
Adjusted estimate 1.91 (1.06 to 3.44) 1.28 (0.82 to .00) 
a User of pain medication was defined as participant t king pain medication of any kind on a regular basis 
during the previous week; the estimates were adjusted for site; the crude estimate was similar to the adjusted 
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Table 4. Improvements of at least 15% and Number Needed to Treat (NNT) a 690 
Outcome 
 
Patients eligible for TKR Patients not eligible for TKR 
Proportion 
improving at least 
15% in TKR 
followed by non-
surgical group 
(95% CI)  
Proportion 




NNTB (95% CI) Proportion 
improving at least 
15% in non-
surgical group 
(95% CI)  
Proportion 
improving at least 
15% in written 
advice group (95% 
CI) 
NNTB (95% CI) 
KOOS4 from 
baseline to 2 
years 
0.86 (0.72 to 0.94) 0.64 (0.49 to 0.76) 4.5 (2.5 to 19.9) 0.70 (0.55 to 0.81) 0.57 (0.42 to 0.71) 8.0 (NNTB 3.1 to ∞ 
to NNTH 13.2) 
Mean change in KOOS subscales score    
       Pain 0.84 (0.69 to 0.92) 0.70 (0.55 to 0.82) 7.4 (NNTB 3.3 to ∞ 
to NNTH 27.8) 
0.67 (0.52 to 0.80) 0.60 (0.44 to 0.73) 12.7 (NNTB 3.6 to 
∞ to NNTH 8.2) 
         
Symptoms 
0.79 (0.64 to 0.89) 0.55 (0.41 to 0.69) 4.2 (2.4 to 19.8) 0.65 (0.50 to 0.78) 0.52 (0.37 to 0.67) 7.8 (NNTB 3.0 to ∞ 
to NNTH 13.2) 
       ADL 0.81 (0.67 to 0.91) 0.64 (0.49 to 0.76) 5.7 (NNTB 2.8 to ∞ 
to NNTH 230.4) 
0.63 (0.48 to 0.76) 0.50 (0.35 to 0.65) 7.7 (NNTB 3.0 to ∞ 
to NNTH 13.3) 
       Sport/Rec 0.93 (0.80 to 0.98) 0.66 (0.51 to 0.78) 3.7 (2.3 to 8.7) 0.63 (0.48 to 0.76) 0.86 (0.71 to 0.94) -4.4 (-19.4 to -2.5) 
      QOL 0.88 (0.74 to 0.95) 0.66 (0.51 to 0.78) 4.5 (2.6 to 17.2) 0.76 (0.61 to 0.86) 0.67 (0.51 to 0.79) 10.6 (NNTB 3.5 to 
∞ to NNTH 10.6) 
a KOOS4: The mean score of four out of five of the Knee injury and Osteoarthritis Outcome Score subscales covering Pain, Symptoms, Function in 
daily living (ADL) and Quality of life (QOL), with scores ranging from 0 to 100 (worst to best scale); Sport/Rec: Function in sport and recreation; NNT 
was estimated using the formula 1/(IER - CER), with IER being the event rate (proportion of responders, i.e., patients improving at least 15%) in the 
TKR followed by non-surgical group/the non-surgical group and CER the event rate in the non-surgical group/written advice group, with 95% CIs 
derived from the reciprocal transformation of the CIs for the difference in proportions 35,36; CIs that include both positive and negative values can be 
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